Abstract Submission Has Now Ended
|
ISTH 2017 welcomed abstract submissions from clinicians, scientists, academics and students. ISTH members and non-members submitted abstracts for consideration.
Embargoed text of abstracts will be made available about two weeks prior to the meeting, on June 23, on the official online program as well as via a compilation available from Research and Practice in Thrombosis and Haemostasis (RPTH). Prior to this, only abstract titles will be available online. Full text of Late Breaking Oral Abstracts are now available here. In an effort to make abstract and poster preparation as easy and professional as possible, the ISTH offers the following services:
Abstract GuidelinesAbstracts can only be submitted online via the abstract submission form. Abstracts sent by post or email will not be accepted. No exceptions will be made. The content of the abstract must be related to one of the topics listed below. To ensure smooth scoring of papers, the topic of your work must be selected during the submission process.
|
Important DatesLate-March, 2017:
Notification will be sent to submitters May 24, 2017: Final late-breaking abstract deadline Please note: Abstracts received after the deadline will not be accepted Professional Services |
|
Atherothrombosis & Stroke
Atherosclerosis Cardiovascular Risk Factors Ischemia-reperfusion Injury Myocardial Infarction Peripheral Vascular Disease Stroke Coagulant & Anticoagulant Mechanisms Animal Models in Thrombosis & Hemostasis Coagulation Factors and Inhibitors Coagulation Proteins Beyond Hemostasis Contact Pathway FVIII/IX Protein C Pathway Regulation of Coagulation Tissue Factor Pathway Coagulation Signaling & Immunity Complement and Hemostatic System Hemostatic Signaling Infection & Hemostatic Factors Inflammation and Sepsis Innate & Adaptive Immunity Platelets & Inflammation Protease Activated Receptors Diagnostics and OMICs Bioinformatics & Systems Biology Biomarkers of Thrombosis & Hemostasis Epigenetics Laboratory Diagnostic Nanotechnology OMICs Fibrinolysis & Proteolysis Cellular & Tumor Proteases Coagulation and Cancer Fibrinogen and Factor XIII Fibrinolytic Factors and Inhibitors Thrombolytic Therapy Hemorrhagic Disorders, Hemophilia Acquired Hemorrhagic Coagulation Disorders Disseminated Intravascular Coagulation Hemophilia - Basic Hemophilia - Clinical Hemophilia Gene Therapy Hemorrhagic Disorders, Pediatric Aspects Management of Bleeding & Trauma Novel Biotherapeutics in Hemophilia Rare Bleeding Disorders VWF and von Willebrand Disease Management of Thromboembolism Atrial Fibrillation DOACs |
Heparins & Heparinoids
Novel Anticoagulants Post-thrombotic Syndrome Pregnancy Complications Thromboembolism, Pediatric Aspects Vitamin K Antagonists Nurses & Allied Health Pathogenesis of Thromboembolism Antiphospholipid Syndrome Cancer-Associated Thrombosis Genetic Risk Factors of Thrombosis Hemostasis & Organ Dysfunction Microparticles Thrombophilia Pediatrics Diagnosis and management of inherited bleeding disorders in children Diagnosis and management of acquired bleeding disorders in children Epidemiology of pediatric thrombosis Diagnosis of pediatric thrombosis Anticoagulant prophylaxis and treatment in children Platelets – Basic Megakaryocytes & Thrombopoiesis Platelet Antagonists Platelets Beyond Hemostasis Platelet Function and Interactions Platelet Proteomics and Genomics Platelet Receptors Platelet Signaling Platelets – Clinical ADAMTS13/TTP Antiplatelet Therapy HIT and ITP HUS/Thrombotic Microangiopathies Platelet Disorders, Acquired Platelet Disorders, Inherited Platelets, Pediatric Aspects Transfusion & Biotherapeutics Blood Components, Production and Substitution Cellular Therapies & Blood Cell Farming Novel Biomolecules Patient Blood Management Safety & Inactivation of Blood Components Vascular Biology & Angiogenesis Angiogenesis & Vasculogenesis Blood Cells and Vessel Wall Endothelial Cell Signaling Non-coding RNAs Vascular Progenitor and Stem Cells |
Overall Abstract Guidelines:
- The abstract must address scientific questions, detail clinical observations, or contain primary scientific data.
- Abstracts submitted for ISTH 2017 Congress are embargoed from the time of submission. This means that the data in the abstract cannot be submitted to other meetings once submitted for the ISTH 2017 Congress. Likewise, abstracts must contain original information, not submitted, published or presented elsewhere prior to submission.
- The first / presenting author is responsible for ensuring that all authors have read the abstract and agreed to be co-authors.
- Abstracts that have been submitted to a previous conference in the same specialty, published or unpublished, will not be accepted.
- The Scientific Committee retains the right to reject abstracts containing previously submitted or presented data as they see fit.
- All research and studies in submitted abstracts that involve human subjects or experimental animals must comply with the Declaration of Helsinki.
- In clinical studies, please state whether informed consent was obtained and whether the study was approved by a recognized medical ethics committee.
- If off-label use of drugs was involved in the study, please state this clearly.
- If the research included in your abstract was supported by a pharmaceutical or diagnostics company, you can indicate this when submitting your abstract.
- Please indicate the funding agency of your work if applicable.
- The abstract title and text may not contain trade names. The Scientific Committee reserves the right to replace trade names in accepted abstracts.
- Do not slice results from the same study into multiple abstracts. The Scientific Committee reserves the right to reject abstracts when inappropriate slicing of data is suspected.
- Similarly, do not submit a copy or close copy of an abstract under more than 1 topic. Abstracts that appear to be submitted multiple times under different topics will be rejected.
- Abstracts should be submitted in clear English to allow the reviewers to focus on the scientific content of the abstract. Non-English speaking authors are encouraged to have their abstract checked for grammar and spelling.
- For standardization, the acceptable length of the abstract is a maximum of 2,000 characters including non-visible characters, such as spaces and line breaks. This does not include the author’s details, titles, tables and figures.
- Abstracts can be saved in "Draft” status to be re-edited and modified until the submission deadline (February 1, 2017, 11:59 CET). Therefore, the submitter will be required to create a user account.
- The submitted / draft abstracts cannot be edited after the submission deadline.
- Abstracts fulfilling all criteria can be saved and submitted. You can still make edits to abstracts that have been submitted, but you will need to re-submit it before the deadline to be considered.
- Only abstracts that have been submitted properly will be considered for the meeting.
- No revisions can be made after the abstract deadline.
- The abstract should be structured into the following sections:
- A title which clearly indicates the nature of the investigation
- Background
- Aims
- Methods, which should contain sufficient information to be able to understand the experimental design, the analytical techniques and the statistics used in the study
- Results, which should contain objective data to answer the scientific question(s). A maximum of two total tables or figures may be submitted with this section. Please be sure to number each table and figure and cite each table and figure in the abstract text.
- Conclusion (or Conclusions) which should provide only conclusions of the study directly supported by the results, along with implications for clinical practice, avoiding speculation and overgeneralization.
- Figures may be submitted with a maximum file size is 10 MB with a resolution of 300 dpi. Figures are allowed in the following formats: PNG, GIF, JPG.
- Tables are allowed with a maximum size of 10 columns x 10 rows. Characters in your table will NOT count towards your 2,000 character count. Tables should be added using the tool in the submitter and not as an image file.
- Adding Co-authors: please fill out the family names, first names, and institute, city, country and email addresses of the co-authors.
- Conflict of interest: It is the intent of the ISTH to provide high-quality sessions focused on educational content that is free from commercial influence or bias. Thus the submitting author of an abstract is requested to declare any potential conflicts of interest for the presenting author during abstract submission.
- Abbreviations should be defined.
- The submission of an abstract constitutes a formal commitment by the submitting (presenting) author to present the abstract (if accepted) in the session and the time assigned by the Scientific Committee. Registration fees will not be waived.
- Please ensure your abstract does not contain spelling, grammar, or scientific mistakes, as it will be reproduced exactly as submitted. Linguistic accuracy is your responsibility. No proof reading will be done.
- No revisions can be made after the abstract deadline.
- The presenting author of the abstract must be registered for the meeting.
Late-Breaking Abstracts
A ‘shell’ or preliminary abstract is due by the February 1, 2017 deadline in order to be considered for the meeting. Late-breaking abstracts are those whose results and conclusion which will not be available until after the abstract submission deadline. You will need to tick ‘Yes’ to it being a late-breaking abstract, during the submission process. You will be notified with instructions on how to update your abstract to include the results and conclusions which will need to be submitted by May 24, 2017. If the results are not obtained by the deadline the abstract will be withdrawn.
A ‘shell’ or preliminary abstract is due by the February 1, 2017 deadline in order to be considered for the meeting. Late-breaking abstracts are those whose results and conclusion which will not be available until after the abstract submission deadline. You will need to tick ‘Yes’ to it being a late-breaking abstract, during the submission process. You will be notified with instructions on how to update your abstract to include the results and conclusions which will need to be submitted by May 24, 2017. If the results are not obtained by the deadline the abstract will be withdrawn.
Language Setting of Your Keyboard
The keyboard configuration of computers in non-Western countries may cause problems with the printing of the abstracts when special non-Western characters are used. To avoid these problems the language setting of your computer should be changed. To do this select "Start" then Settings", then "Control Panel" and then choosing "Keyboard." Once in this menu, set the language of your computer to English (United States) or US (International). Next, open MS Word (or the word processing software you are using) and set the font type to Arial. In the preparation of your abstract, if you require certain special characters that are not available, (e.g. '±', '®', 'μ'), use the insert symbol feature (special characters). To do this, select Arial as the font (unicoded, if possible), then select the required character, and copy and paste the symbol into the text of the abstract. If a special character is still not available, describe the character, e.g. 'alpha’.
The keyboard configuration of computers in non-Western countries may cause problems with the printing of the abstracts when special non-Western characters are used. To avoid these problems the language setting of your computer should be changed. To do this select "Start" then Settings", then "Control Panel" and then choosing "Keyboard." Once in this menu, set the language of your computer to English (United States) or US (International). Next, open MS Word (or the word processing software you are using) and set the font type to Arial. In the preparation of your abstract, if you require certain special characters that are not available, (e.g. '±', '®', 'μ'), use the insert symbol feature (special characters). To do this, select Arial as the font (unicoded, if possible), then select the required character, and copy and paste the symbol into the text of the abstract. If a special character is still not available, describe the character, e.g. 'alpha’.
After Submission
An international panel of experts will review the abstracts. Each abstract will be reviewed by 4-6 different experts. Abstracts may be selected for oral presentation, poster presentation, or rejection. The first author will be notified in late-March 2017, at the email address provided during submission, about whether or not their abstract has been accepted.
The reviewers will judge the abstracts according to the following criteria:
Please note:
All accepted abstracts will be published online only as an addendum supplement to the ISTH open access journal, Research and Practice in Thrombosis and Haemostasis and will be made available on the ISTH 2017 Congress website at the time of the Congress.
An international panel of experts will review the abstracts. Each abstract will be reviewed by 4-6 different experts. Abstracts may be selected for oral presentation, poster presentation, or rejection. The first author will be notified in late-March 2017, at the email address provided during submission, about whether or not their abstract has been accepted.
The reviewers will judge the abstracts according to the following criteria:
- Is the abstract original?
- Does it address an important scientific question?
- Is the abstract clearly written with all salient facts?
- Does the work adhere to ethical guidelines?
- Is there evidence of statistical method if appropriate?
- Are the conclusions justified by the results?
Please note:
- No revisions can be made after the abstract deadline.
- There will be room for a very limited number of late breaking abstracts with a later deadline. The author still needs to submit a ‘shell’ abstract by February 1, 2017 with sufficient information for the reviewers to understand the importance of the data. The author is required to select the Submission Type ‘Late Breaking Abstract’. A final abstract has to be submitted to the Congress Secretariat by May 24, 2017.
- The best scoring abstracts will be selected for oral presentation.
- Authors of abstracts selected for oral presentation will be informed about the type and date of the session, and presentation guidelines will be provided.
- Poster presenters will be informed about the date of the poster exhibition and will receive guidelines for their poster. Posters will be organized within the session using the topics chosen by the submitter in the online system.
All accepted abstracts will be published online only as an addendum supplement to the ISTH open access journal, Research and Practice in Thrombosis and Haemostasis and will be made available on the ISTH 2017 Congress website at the time of the Congress.
Withdrawal Policy
If authors wish to withdraw their abstracts from presentation or publication they are requested to send a letter via e-mail to [email protected] before May 24, 2017.
Withdrawn abstracts cannot be presented nor will these be published.
If authors wish to withdraw their abstracts from presentation or publication they are requested to send a letter via e-mail to [email protected] before May 24, 2017.
Withdrawn abstracts cannot be presented nor will these be published.
Travel Grants
The ISTH offers two different awards that are provided in the form of travel grants. The Young Investigator Award and Reach-the-World Award are available to those who are first authors on an abstract. Click here to learn more.
Technical Requirements
The online abstract submission system works best with Internet Explorer 7.0 or higher or Mozilla Firefox 3.0 or higher. Cookies and JavaScript need to be enabled.
The online abstract submission system works best with Internet Explorer 7.0 or higher or Mozilla Firefox 3.0 or higher. Cookies and JavaScript need to be enabled.